Value in health regional issues最新文献_第9页

Patient Preferences for Out-of-Hospital Cardiac Arrest Care in South Africa: A Discrete Choice Experiment 南非患者对院外心脏骤停护理的偏好：离散选择实验

IF 2

Value in health regional issues Pub Date : 2024-06-09 DOI: 10.1016/j.vhri.2024.101006

Kalin Werner PhD , Willem Stassen PhD , Elzarie Theron MA , Lee A. Wallis PhD , Tracy K. Lin PhD

{"title":"Patient Preferences for Out-of-Hospital Cardiac Arrest Care in South Africa: A Discrete Choice Experiment","authors":"Kalin Werner PhD , Willem Stassen PhD , Elzarie Theron MA , Lee A. Wallis PhD , Tracy K. Lin PhD","doi":"10.1016/j.vhri.2024.101006","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.101006","url":null,"abstract":"<div><h3>Objective</h3><p>This study examined the trade-offs low-resource setting community members were willing to make in regard to out-of-hospital cardiac arrest care using a discrete choice experiment survey.</p></div><div><h3>Methods</h3><p>We administered a discrete choice experiment survey to a sample of community members 18 years or older across South Africa between April and May 2022. Participants were presented with 18 paired choice tasks comprised of 5 attributes (distance to closest adequate facility, provider of care, response time, chances of survival, and transport cost) and a range of 3 to 5 levels. We used mixed logit models to evaluate respondents’ preferences for selected attributes.</p></div><div><h3>Results</h3><p>Analyses were based on 2228 responses and 40 104 choice tasks. Patients valued care with the shortest response time, delivered by the highest qualified individuals, which placed them within the shortest distance of an adequate facility, gave them the highest chance of survival, and costed the least. In addition, patients preferred care delivered by their family members over care delivered by the lay public. The highest mean willingness-to-pay for increased survival is 11 699 South African rand (ZAR), followed by distance to health facility (8108 ZAR), and response time (5678 ZAR), and the lowest for increasing specialization of provider (1287 ZAR).</p></div><div><h3>Conclusions</h3><p>In low-resource settings, it may align with patients’ preference to include targeted resuscitation training for family members of individuals with high-risk for cardiac arrest as a part of out-of-hospital cardiac arrest intervention strategies.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 101006"},"PeriodicalIF":2.0,"publicationDate":"2024-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212109924000396/pdfft?md5=908de7dd839dad11e6a6c014a052c2f4&pid=1-s2.0-S2212109924000396-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141294851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hospital Healthcare Resource Utilization and Associated Hospital Costs of Patients With Lupus Nephritis in China: A National Administrative Claim Database Study 中国狼疮性肾炎患者的医院医疗资源利用和相关住院费用：全国行政报销数据库研究

IF 2

Value in health regional issues Pub Date : 2024-06-08 DOI: 10.1016/j.vhri.2024.101001

Xin He PhD , Xiaochen Zhu MS , Zhiliu Tang PhD , Kerry Gairy MSc , Patricia Juliao Ph.D , Zongxi Wu BSc , Sheng Han PhD

{"title":"Hospital Healthcare Resource Utilization and Associated Hospital Costs of Patients With Lupus Nephritis in China: A National Administrative Claim Database Study","authors":"Xin He PhD , Xiaochen Zhu MS , Zhiliu Tang PhD , Kerry Gairy MSc , Patricia Juliao Ph.D , Zongxi Wu BSc , Sheng Han PhD","doi":"10.1016/j.vhri.2024.101001","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.101001","url":null,"abstract":"<div><h3>Objectives</h3><p>Assess hospital healthcare resource utilization (HCRU) and associated hospital costs of patients with lupus nephritis (LN) in China and compare these outcomes with a systemic lupus erythematosus (SLE) cohort (SLE with/without LN) as well as exploring the effect of end-stage kidney disease (ESKD).</p></div><div><h3>Methods</h3><p>This retrospective administrative claims-based analysis identified patients with SLE and SLE with LN from China using diagnosis codes and keywords. Patients with LN were subcategorized by presence of ESKD. Outcomes included all-cause and disease-specific HCRU (defined as healthcare visits including inpatient and outpatient visits) and medical costs (in 2022 US dollars).</p></div><div><h3>Results</h3><p>In total, 3645 patients with SLE were included, of whom 404 (11%) had LN. Among those with LN, 142 (35%) had ESKD. Median (interquartile range) all-cause healthcare visits per patient per month (PPPM) was significantly greater for patients with LN (2.08 [4.01]) vs SLE (0.92 [1.64]; <em>P</em> < .0001). Patients with LN and ESKD (3.00 [4.18]) had numerically more all-cause healthcare visits PPPM compared with LN patients without ESKD (1.50 [3.45]). Median all-cause costs PPPM were significantly greater among patients with LN ($287.46 [477.15]) vs SLE ($113.09 [267.39]; <em>P</em> < .0001) and numerically higher for patients with LN and ESKD ($466.29 [958.90]) vs LN without ESKD ($223.50 [319.56]).</p></div><div><h3>Conclusions</h3><p>Chinese patients with LN had greater HCRU and hospital healthcare costs compared with the general SLE cohort. This burden was higher for those with ESKD. These data highlight the substantial HCRU among patients with LN in China, especially those with ESKD, suggesting the need for early diagnosis and timely management of LN to mitigate the economic burden.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 101001"},"PeriodicalIF":2.0,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141291991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-Effectiveness of Increasing Access to Colorectal Cancer Diagnosis: Analysis From Thailand 增加大肠癌诊断机会的成本效益：泰国分析

IF 2

Value in health regional issues Pub Date : 2024-06-07 DOI: 10.1016/j.vhri.2024.101010

Peeradon Wongseree MD , Zeynep Hasgul MSc , Mohammad S. Jalali PhD

{"title":"Cost-Effectiveness of Increasing Access to Colorectal Cancer Diagnosis: Analysis From Thailand","authors":"Peeradon Wongseree MD , Zeynep Hasgul MSc , Mohammad S. Jalali PhD","doi":"10.1016/j.vhri.2024.101010","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.101010","url":null,"abstract":"<div><h3>Objectives</h3><p>The purpose of this study is to evaluate the cost-effectiveness of increasing access to colorectal cancer (CRC) diagnosis, considering resource limitations in Thailand.</p></div><div><h3>Methods</h3><p>We analyzed the cost-effectiveness of increasing access to fecal immunochemical test screening (strategy I), symptom evaluation (strategy II), and their combination through healthcare and societal perspectives using Colo-Sim, a simulation model of CRC care. We extended our analysis by adding a risk-stratification score (RS) to the strategies. We analyzed all strategies under the currently limited annual colonoscopy capacity and sufficient capacity. We estimated quality-adjusted life-years (QALYs) and costs over 2023 to 2047 and performed sensitivity analyses.</p></div><div><h3>Results</h3><p>Annual costs for CRC care will increase over 25 years in Thailand, resulting in a cumulative cost of 323B Thai baht (THB). Each strategy results in higher QALYs gained and additional costs. With the current colonoscopy capacity and willingness-to-pay threshold of 160 000 THB, strategy I with and without RS is not cost-effective. Strategy II + RS is the most cost-effective, resulting in 0.68 million QALYs gained with additional costs of 66B THB. Under sufficient colonoscopy capacity, all strategies are deemed cost-effective, with the combined approach (strategy I + II + RS) being the most favorable, achieving the highest QALYs (1.55 million) at an additional cost of 131 billion THB. This strategy also maintains the highest probability of being cost-effective at any willingness-to-pay threshold above 96 000 THB.</p></div><div><h3>Conclusions</h3><p>In Thailand, fecal immunochemical test screening, symptom evaluation, and RS use can achieve the highest QALYs; however, boosting colonoscopy capacity is essential for cost-effectiveness.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 101010"},"PeriodicalIF":2.0,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141286193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Simplified Chronic Hepatitis B Antiviral Initiation Criteria in Thailand: An Economic Evaluation 泰国简化慢性乙型肝炎抗病毒治疗启动标准：经济评估

IF 2

Value in health regional issues Pub Date : 2024-06-07 DOI: 10.1016/j.vhri.2024.101011

Piyameth Dilokthornsakul PharmD, PhD , Ratree Sawangjit PhD , Pisit Tangkijvanich MD , Maneerat Chayanupatkul MD , Unchalee Permsuwan PhD

{"title":"Simplified Chronic Hepatitis B Antiviral Initiation Criteria in Thailand: An Economic Evaluation","authors":"Piyameth Dilokthornsakul PharmD, PhD , Ratree Sawangjit PhD , Pisit Tangkijvanich MD , Maneerat Chayanupatkul MD , Unchalee Permsuwan PhD","doi":"10.1016/j.vhri.2024.101011","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.101011","url":null,"abstract":"<div><h3>Objectives</h3><p>Criteria for antiviral treatment initiation in Thailand were complex and difficult to implement. This study determined the cost-effectiveness of 2 simplified antiviral treatment initiation criteria among patients with chronic hepatitis B in Thailand.</p></div><div><h3>Methods</h3><p>A hybrid model of the decision tree and Markov model was developed. Two simplified antiviral treatment initiation criteria were the expanded criteria, treating patients with hepatitis B surface antigen positive and viral load (hepatitis B virus deoxyribonucleic acid) >2000 IU/mL or cirrhosis by tenofovir alafenamide (TAF), and the test-and-treat criteria, treating patients with hepatitis B surface antigen positive and viral load >10 IU/mL or cirrhosis by TAF. PubMed was searched from its inception to July 2023 to identify input parameters. Best supportive care was chosen for patients who were ineligible for TAF. Incremental cost-effectiveness ratio per quality-adjusted life-year (QALY) was calculated.</p></div><div><h3>Results</h3><p>The expanded criteria and the test-and-treat could reduce the occurrence of patients progressing to hepatocellular carcinoma. In particular, both criteria could reduce 4846 new cases of hepatocellular carcinoma per 100 000 patients. The incremental cost-effectiveness ratios for the expanded criteria and the test-and-treat criteria were 24 838 Thai baht (THB)/QALY and 163 060 THB/QALY, respectively.</p></div><div><h3>Conclusions</h3><p>At the current willingness to pay of 160 000 THB/QALY, the expanded criteria were cost-effective, but the test-and-treat criteria were not cost-effective to be the simplified antiviral treatment initiation criteria for patients with chronic hepatitis B in Thailand.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 101011"},"PeriodicalIF":2.0,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141286194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Societal Preferences for Subsidizing Treatments Targeting Patients With Advanced Illness: A Discrete Choice Experiment 补贴晚期患者治疗的社会偏好：离散选择实验

IF 2

Value in health regional issues Pub Date : 2024-06-04 DOI: 10.1016/j.vhri.2024.101003

Drishti Baid BSocSci , Darius N. Lakdawalla PhD , Eric A. Finkelstein PhD

{"title":"Societal Preferences for Subsidizing Treatments Targeting Patients With Advanced Illness: A Discrete Choice Experiment","authors":"Drishti Baid BSocSci , Darius N. Lakdawalla PhD , Eric A. Finkelstein PhD","doi":"10.1016/j.vhri.2024.101003","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.101003","url":null,"abstract":"<div><h3>Objectives</h3><p>Cost-effectiveness analyses are increasingly used to inform subvention decisions for moderately life extending treatments but apply several simplifying assumptions that may be inconsistent with public preferences. Contrary to standard assumptions, we hypothesize that societal willingness to allocate public funding toward these treatments is (1) diminishing for incremental improvements in survival and quality of life (QoL) and (2) greater for subvention policies that exclude the oldest old (>80 years).</p></div><div><h3>Methods</h3><p>We tested these hypotheses using a web-based discrete choice experiment (<em>n</em> = 425) in Singapore. In each of 5 questions, respondents were shown 2 hypothetical treatments targeting patients with an expected prognosis of 2 months at very poor QoL and asked which treatment they wanted the government to subsidize, if any. Treatments were defined by 4 attributes: cost to the government, age of beneficiaries, expected gain in survival (2-12 months), and QoL (poor, fair, and good).</p></div><div><h3>Results</h3><p>Latent class models were used to analyze results. Results revealed 2 classes. In the majority class (69.7% of sample), respondents value incremental gains in survival and QoL at a diminishing rate. Their willingness to allocate public funding estimates (Singapore dollars 16 825-91 027 per patient per month) were much higher than traditional cost-effectiveness thresholds. In the second class, respondents were unwilling to subsidize treatments offering less than 2 months of life extension or poor QoL. Neither class preferred subvention policies that exclude the oldest old.</p></div><div><h3>Conclusions</h3><p>These findings suggest that the Singapore government should consider cost-effectiveness thresholds that rise with increases in life extension. Age-based restrictions should not be imposed.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 101003"},"PeriodicalIF":2.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141244999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-Term Cost-Effectiveness of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Adults With Type 1 Diabetes in Iran 伊朗 1 型糖尿病成人持续血糖监测与自我血糖监测的长期成本效益。

IF 2

Value in health regional issues Pub Date : 2024-05-30 DOI: 10.1016/j.vhri.2024.101002

Mohsen Choband Molaee PharmD , Zahra Gharib Naseri PharmD, PhD , Masoud Ali Karami PharmD, PhD

{"title":"Long-Term Cost-Effectiveness of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Adults With Type 1 Diabetes in Iran","authors":"Mohsen Choband Molaee PharmD , Zahra Gharib Naseri PharmD, PhD , Masoud Ali Karami PharmD, PhD","doi":"10.1016/j.vhri.2024.101002","DOIUrl":"10.1016/j.vhri.2024.101002","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aimed to determine long-term cost-effectiveness of continuous glucose monitoring (CGM) technology versus self-monitoring of blood glucose (SMBG) in adults with type 1 diabetes (T1D) using multiple daily injections in Iran.</p></div><div><h3>Methods</h3><p>According to available data, the long-term costs and clinical outcomes of CGM and SMBG were estimated using the Sheffield Type 1 Diabetes Model, with a lifetime horizon from a payer’s perspective. The primary outcome was the cost per quality-adjusted life year (QALY) gained.</p></div><div><h3>Results</h3><p>The lifetime cost-effectiveness analysis demonstrated that on average, the use of CGM increased life expectancy by 1.32 years and QALYs by 1.63, compared with SMBG. The CGM group had an average discounted total cost of $40 093 US dollars, whereas the SMBG group had an average discounted total cost of $13 366. This resulted in an incremental cost-effectiveness ratio (ICER) of $16 386 per QALY gained, which is less than the threshold of 3 times the gross domestic product (GDP) per capita of Iran ($24 561).</p></div><div><h3>Conclusions</h3><p>Considering 3 times the GDP per capita as the threshold, CGM is likely to be cost-effective in Iran. However, for CGM to be very cost-effective (ie, have an ICER less than 1 times the GDP per capita) and presumably more accessible, the price of CGM should decrease to $40 per sensor, each with a lifespan of 14 days.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 101002"},"PeriodicalIF":2.0,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141184738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges and Reflections on Pandemic Disinformation: The Case of Hydroxychloroquine and the Implications for Global Public Health 大流行病虚假信息的挑战与思考：羟氯喹案例及其对全球公共卫生的影响

IF 2

Value in health regional issues Pub Date : 2024-05-24 DOI: 10.1016/j.vhri.2024.101005

Heslley Machado Silva PhD

{"title":"Challenges and Reflections on Pandemic Disinformation: The Case of Hydroxychloroquine and the Implications for Global Public Health","authors":"Heslley Machado Silva PhD","doi":"10.1016/j.vhri.2024.101005","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.101005","url":null,"abstract":"<div><p>This text addresses the implications of misinformation during the COVID-19 pandemic, focusing on the use of hydroxychloroquine (HCQ) and other drugs based on a specific publication. The article titled “Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate,” published in 2024 in the journal Biomedicine and Pharmacotherapy, reveals 17 000 deaths associated with the inappropriate use of HCQ in 6 countries, excluding Brazil and India. The dissemination of ineffective drugs, the persistence in recommending HCQ in Brazil, and the lack of an effective response from academia underscore the fragility of public health systems under pressure. Transparent communication between the scientific community and the public is vital, particularly considering studies, such as the one published in Nature Communications in 2021, which warns of the risks of chloroquine. The text highlights the influence of social media in spreading unverified information and emphasizes the need for criminal liability for those contributing to the spread of misinformation. It concludes by underlining the importance of learning from past mistakes to build a more resilient and informed future in the field of public health.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 101005"},"PeriodicalIF":2.0,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141089810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Process of Listing Prostheses and Medical Devices in Thailand’s Universal Health Coverage 将假肢和医疗器械列入泰国全民医保的过程

IF 2

Value in health regional issues Pub Date : 2024-05-22 DOI: 10.1016/j.vhri.2024.100990

Manthana Laichapis PharmD , Thanisa Thathong PharmD , Supisara Kanjanaphrut PharmD , Sirada Thansuwanwong PharmD , Yotsaya Kunlamas PharmD , Puree Anantachoti PhD , Bunchai Chongmelaxme PhD

{"title":"The Process of Listing Prostheses and Medical Devices in Thailand’s Universal Health Coverage","authors":"Manthana Laichapis PharmD , Thanisa Thathong PharmD , Supisara Kanjanaphrut PharmD , Sirada Thansuwanwong PharmD , Yotsaya Kunlamas PharmD , Puree Anantachoti PhD , Bunchai Chongmelaxme PhD","doi":"10.1016/j.vhri.2024.100990","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100990","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aimed to characterize the processes of listing prostheses and medical devices in all insurance schemes.</p></div><div><h3>Methods</h3><p>A literature review was performed, and in-depth interviews were conducted with the representatives of 6 insurance agencies. Civil Servant Medical Benefits Scheme (CSMBS), Social Security Scheme, Local Government Officer Scheme (LGOS), State Enterprise Scheme (SES), Universal Coverage Scheme (UCS), and Non-Thai Resident Scheme (NTRS).</p></div><div><h3>Results</h3><p>The outcomes of interest were structure details and the body of the working groups, listing processes, and key assessment criteria. Each insurance scheme’s process can be summarized in 5 steps: (1) receiving the proposed topics of health technologies, (2) screening, (3) selection, (4) consideration, and (5) approval and publicization. Notably, the organizational structures and working group compositions vary across schemes, leading to differences in process activities and assessment criteria. LGOS and SES are exceptions because they follow the application process of CSMBS. UCS demonstrates the most transparent process, providing specific working groups that are competent in undertaking each activity. The processes of listing prostheses and medical devices vary across health insurance in Thailand, leading to varying numbers of health technologies covered by insurance schemes.</p></div><div><h3>Conclusions</h3><p>This study characterizes prostheses and medical device listing processes in 6 Thai Universal Health Coverage insurance schemes (CSMBS, Social Security Scheme, UCS, LGOS, SES, and Non-Thai Resident Scheme). Variations in processes result in differing technology listings. It offers essential insights for healthcare professionals and policy makers.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"42 ","pages":"Article 100990"},"PeriodicalIF":2.0,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141083347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Impact of COVID-19 on Healthcare Utilization in Turkey COVID-19 对土耳其医疗利用率的影响

IF 2

Value in health regional issues Pub Date : 2024-05-15 DOI: 10.1016/j.vhri.2024.101000

Zeynep B. Uğur PhD , Ayşenur Durak MSc

{"title":"The Impact of COVID-19 on Healthcare Utilization in Turkey","authors":"Zeynep B. Uğur PhD , Ayşenur Durak MSc","doi":"10.1016/j.vhri.2024.101000","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.101000","url":null,"abstract":"<div><h3>Objectives</h3><p>This study investigates the impact of the COVID-19 pandemic on healthcare utilization in Turkey.</p></div><div><h3>Methods</h3><p>We utilized individual-level data derived from Turkish Statistical Institute’s annual surveys between 2014 and 2022 and estimated probit regression models.</p></div><div><h3>Results</h3><p>We find that COVID-19 pandemic reduced healthcare utilization by 11.8% after taking into account a large set of background variables. Although our study finds that the elderly and those with health problems are more likely to use healthcare services under normal circumstances, the COVID-19 pandemic has caused notable drops in the healthcare utilization among the elderly (−6.5%) and those with health problems (−3.8%). Although those without health insurance had lower utilization of healthcare services before the pandemic, during the pandemic they were not particularly hit.</p></div><div><h3>Conclusion</h3><p>We conclude that the pandemic did not lower the healthcare utilization in Turkey because of the supply constraints. Also, the evidence points to the reduced demand due to the fear of contagion rather than financial concerns.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 101000"},"PeriodicalIF":2.0,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140947918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mortalidad, Secuelas Clínicas y Calidad de Vida Luego del Alta de Unidades de Cuidados Intensivos en Pacientes con COVID-19: Estudio Multicéntrico Descriptivo en Argentina COVID-19 患者从重症监护病房出院后的死亡率、临床后遗症和生活质量：阿根廷的一项多中心描述性研究

IF 2

Value in health regional issues Pub Date : 2024-05-09 DOI: 10.1016/j.vhri.2024.100989

Fernando Argento Ms(c) , Manuel Donato Ms(c) , Dario Villalba Spec , Marisol García Sarubbio Spec , Anabella Giménez PT , Agustin Ciapponi PhD , Federico Augustovski PhD

{"title":"Mortalidad, Secuelas Clínicas y Calidad de Vida Luego del Alta de Unidades de Cuidados Intensivos en Pacientes con COVID-19: Estudio Multicéntrico Descriptivo en Argentina","authors":"Fernando Argento Ms(c) , Manuel Donato Ms(c) , Dario Villalba Spec , Marisol García Sarubbio Spec , Anabella Giménez PT , Agustin Ciapponi PhD , Federico Augustovski PhD","doi":"10.1016/j.vhri.2024.100989","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100989","url":null,"abstract":"<div><h3>Objective</h3><p>Patients with COVID-19 who require hospitalization in an intensive care unit, in addition to being at risk of presenting premature death, have higher rates of complications. This study aimed to describe mortality, rehospitalizations, quality of life, and symptoms related to postintensive care syndrome (PICS) and prolonged COVID-19 in patients with COVID-19 discharged from the intensive care unit in hospitals in Argentina.</p></div><div><h3>Methods</h3><p>A cross-sectional study was conducted in 4 centers in the Autonomous City and province of Buenos Aires as of December 2022. The variables of interest were mortality after discharge, rehospitalization, health-related quality of life, post-COVID-19–related symptoms, cognitive status, and PICS. Data collection was by telephone interview between 6 and 18 months after discharge.</p></div><div><h3>Results</h3><p>A total of 124 patients/families were contacted. Mortality was 7.3% (95% CI: 3.87-13.22) at 14.46 months of follow-up after discharge. Patients reported a reduction of the EQ-5D-3L visual analog scale of 13.8 points, reaching a mean of 78.05 (95% CI: 73.7-82.4) at the time of the interview. Notably, 54.4% of patients (95% CI: 41.5-66.6) reported cognitive impairment and 66.7% (95% CI: 53.7-77.5) developed PICS, whereas 37.5% (95% CI: 26-50.9) had no symptoms of prolonged COVID-19.</p></div><div><h3>Conclusion</h3><p>The results showed a significant impact on the outcomes studied, consistent with international evidence.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"42 ","pages":"Article 100989"},"PeriodicalIF":2.0,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140901711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0